natgillin/translations-raw huggingface dataset:
Lyxumia given with a basal insulin alone, or with a combination of a basal insulin and metformin, or a combination of a basal insulin and a sulphonylurea resulted in statistically significant reductions in HbA1c and in 2-hour post-prandial glucose after a test- meal compared to placebo.
Zdravilo Lyxumia, uporabljeno z bazalnim insulinom samim ali v kombinaciji z bazalnim insulinom in metforminom ali v kombinaciji z bazalnim insulinom in sulfonilsečnino, je v primerjavi s placebom doseglo statistično značilno znižanje HbA1c in postprandialne glukoze 2 uri po testnem obroku.
Lyxumia has no or negligible influence on the ability to drive or use machines.
Zdravilo Lyxumia nima ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Lyxumia is a clear and colourless solution for injection (injection) filled in a glass cartridge inserted in a pre-filled pen.
Zdravilo Lyxumia je bistra in brezbarvna raztopina za injiciranje (injekcija) v steklenem vložku, vstavljenem v napolnjen injekcijski peresnik.
Lyxumia is administered once daily, within the hour prior to any meal of the day.
Zdravilo Lyxumia se uporablja enkrat na dan, v eni uri pred katerim koli dnevnim obrokom.
Lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control (see sections 4.4 and 5.1 for available data on the different combinations).
Zdravilo Lyxumia je indicirano za zdravljenje odraslih s sladkorno boleznijo tipa 2 za doseganje urejenosti glikemije v kombinaciji z peroralnimi antidiabetiki in/ali bazalnim insulinom takrat, ko uporaba teh zdravil skupaj z dieto in telesno dejavnostjo ne zagotavlja ustrezne urejenosti glikemije (glejte poglavji 4.4 in 5.1 za podatke o različnih kombinacijah, ki so na voljo)
Lyxumia is not recommended in women of childbearing potential not using contraception.
Zdravilo Lyxumia ni priporočljivo za ženske v rodni dobi, ki ne uporabljajo kontracepcije.
Lyxumia is to be injected subcutaneously in the thigh, abdomen or upper arm.
Zdravilo Lyxumia je treba injicirati subkutano v stegno, trebuh ali zgornji del roke.
Lyxumia pen Information
Informacije o peresniku Lyxumia
Lyxumia should be used with caution in patients receiving oral medicinal products that require rapid gastrointestinal absorption, require careful clinical monitoring or have a narrow therapeutic ratio.
Zdravilo Lyxumia je treba previdno uporabljati pri bolnikih, ki peroralno prejemajo zdravila, ki zahtevajo hitro gastrointestinalno absorpcijo, potrebujejo skrbno klinično spremljanje ali imajo ozko terapevtsko razmerje.
Lyxumia should not be administered intravenously or intramuscularly.
Zdravila Lyxumia se ne sme dajati intravensko ali intramuskularno.
Lyxumia should not be given in combination with basal insulin and a sulphonylurea due to increased risk of hypoglycaemia.
Zdravila Lyxumia se ne sme uporabljati v kombinaciji z bazalnim insulinom in sulfonilsečnino, ker se poveča tveganje za hipoglikemijo.
m 48 weeks of double-blind tenofovir disoproxil fumarate followed by 240 weeks open-label.
m 48-tedensko dvojno slepo zdravljenje z dizoproksiltenofovirijevim fumaratom, ki mu sledi 240-tedensko odprto
m 48 weeks of double-blind tenofovir disoproxil fumarate followed by 240 weeks open-label.
m 48-tedensko dvojno slepo zdravljenje z dizoproksiltenofovirijevim fumaratom, ki mu sledi 240-tedensko odprto zdravljenje.
M+P n=338
p-vrednostd
m-Cresol [3.15 mg/ml] Glycerol
Metakrezol [3,15 mg/ml] Glicerol
M-M- RVAXPRO is not to be injected directly into any blood vessel.
Cepiva M-M-RVAXPRO se ne sme injicirati neposredno v katero koli žilo.
M-M- RVAXPRO must not be given during pregnancy, any illness with fever (over 38.5°C) or active untreated tuberculosis (TB).
Cepivo M-M-RVAXPRO se ne sme uporabiti med nosečnostjo, katero koli boleznijo s povišano telesno temperaturo (nad 38,5°C) ali aktivno nezdravljeno tuberkulozo (TB).
M-M-RVAXPRO (or its component vaccines) may develop thrombocytopenia with repeat doses.
M-M-RVAXPRO (ali s cepivi, ki ga sestavljajo), trombocitopenija pojavi po ponovnih odmerkih.
M-M-RVAXPRO - Powder in vial and solvent in pre-filled syringe with one unattached needle – Pack of 1, 10, 20
M-M-RVAXPRO – prašek v viali in vehikel v napolnjeni injekcijski brizgi z eno nepritrjeno iglo – pakiranje po 1, 10, 20
M-M-RVAXPRO - Powder in vial and solvent in pre-filled syringe with two unattached needles - Pack of 1, 10, 20
M-M-RVAXPRO – prašek v viali in vehikel v napolnjeni injekcijski brizgi z dvema nepritrjenima iglama – pakiranje po 1, 10, 20
M-M-RVAXPRO - Powder in vial and solvent in prefilled syringe with attached needle - Pack of 1, 10
M-M-RVAXPRO – prašek v viali in vehikel v napolnjeni injekcijski brizgi s pritrjeno iglo – pakiranje po 1, 10
M-M-RVAXPRO - Powder in vial and solvent in prefilled syringe without needle - Pack of 1, 10, 20
M-M-RVAXPRO – prašek v viali in vehikel v napolnjeni injekcijski brizgi brez igle – pakiranje po 1, 10, 20
M-M-RVAXPRO - Powder in vial and solvent in vial- Pack of 1, 10
M-M-RVAXPRO – prašek v viali in vehikel v viali – pakiranje po 1, 10
M-M-RVAXPRO contains small amounts of weakened forms of the viruses that cause measles, mumps, and rubella.
Cepivo M-M-RVAXPRO vsebuje majhne količine oslabljenih oblik virusov, ki povzročajo ošpice, mumps in rdečke.
M-M-RVAXPRO has not been evaluated in fertility studies.
Cepiva M-M-RVAXPRO niso ovrednotili v študijah plodnosti.
M-M-RVAXPRO is a vaccine that contains live attenuated (weakened) measles, mumps and rubella viruses.
Zdravilo M-M-RVAXPRO je cepivo, ki vsebuje žive (oslabljene) viruse ošpic, mumpsa in rdečk.
M-M-RVAXPRO is a vaccine.
Zdravilo M-M-RVAXPRO je cepivo.
M-M-RVAXPRO is given according to official recommendations.
Cepivo M-M-RVAXPRO se daje le v skladu z uradnimi priporočili.
M-M-RVAXPRO is given as follows:
S cepivom M-M-RVAXPRO se cepi po naslednji shemi:
M-M-RVAXPRO is used to vaccinate against measles, mumps, and rubella (German measles) in adults and children aged 12 months or older.
Cepivo M-M-RVAXPRO se uporablja za cepljenje odraslih in otrok, starejših od 12 let, proti ošpicam, mumpsu in rdečkam (nemškim ošpicam).
M-M-RVAXPRO is very similar to another vaccine for the measles, mumps and rubella vaccine already authorised (M-M-R II) but with a slight difference.
Zdravilo M-M-RVAXPRO je zelo podobno drugemu cepivu proti ošpicam, mumpsu in rdečkam, ki je že odobreno (cepivu M-M-R II), vendar z majhno razliko.
M-M-RVAXPRO powder and solvent for suspension for injection in pre-filled syringe Measles, mumps, and rubella vaccine (live)
M-M-RVAXPRO prašek in vehikel za suspenzijo za injiciranje v napolnjeni injekcijski brizgi cepivo proti ošpicam, mumpsu in rdečkam (živo)
M-M-RVAXPRO powder and solvent for suspension for injection Measles, mumps, and rubella vaccine (live)
M-M-RVAXPRO prašek in vehikel za suspenzijo za injiciranje cepivo proti ošpicam, mumpsu in rdečkam (živo)
M-M-RVAXPRO should be injected into the muscle or under the skin either in the area of the outer thigh or of the upper arm.
Cepivo M-M-RVAXPRO se z injekcijo injicira v mišico ali pod kožo v predel zunanje strani stegna ali nadlakti.
M-M-RVAXPRO should not be given to pregnant females.
Nosečnic se ne sme cepiti s cepivom M-M-RVAXPRO.
M-M-RVAXPRO should not be used in people who may be hypersensitive (allergic) to any measles, mumps or rubella vaccine, or to any of the ingredients, including neomycin (an antibiotic).
Cepiva M-M-RVAXPRO ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) katero koli cepivo proti ošpicam, mumpsu in rdečkam ali katero koli drugo sestavino zdravila, vključno z neomicinom (antibiotikom).
M. catarrhalis: S ≤ 0.5 mg/L and R > 0.5 mg/L
M. catarrhalis: S ≤ 0,5 mg/l in R > 0,5 mg/l
M.A. Number: EU/1/98/064/001
Številka dovoljenja za promet: EU/1/98/064/001
M.A.H: CHIESI FARMACEUTICI S.P.A
Imetnik dovoljenja za promet z zdravilom: CHIESI FARMACEUTICI S.P.A
M06-802 was a randomised open-label study comparing the safety, tolerability and antiviral activity of once daily and twice daily dosing of lopinavir/ritonavir tablets in 599 subjects with detectable viral loads while receiving their current antiviral therapy.
M06-802 je bila randomizirana, odprta študija, ki je primerjala varnost, prenašanje in protivirusno delovanje tablet lopinavirja/ritonavirja enkrat in dvakrat na dan pri 599 preiskovancih z ugotovljivim virusnim bremenom med njihovim trenutnim protivirusnim zdravljenjem.
M1 and M3 have an open beta-lactone ring and extremely weak lipase inhibitory activity (1,000- and 2,500-fold less than orlistat, respectively).
M1 in M3 imata odprt betalaktonski obroč in zelo šibak zaviralni učinek na lipazo (1.000- oziroma 2.500-krat šibkejši od orlistata).
M1 is further metabolised to M2 by one or several cytosolic enzymes.
M1 se nato z enim od več citosolskih encimov presnovi v M2.
M1, but not M2, possesses about 1/3 of the pharmacological activity as compared to its parent in an animal model.
M1, ne pa tudi M2, ima v živalskem modelu v primerjavi z matično spojino približno 1/3 farmakološke aktivnosti.
M184V is associated with about a 2 fold increase in abacavir resistance but does not confer clinical resistance for abacavir.
M184V je povezan s približno 2-kratnim povečanjem odpornosti na abakavir, vendar ne povzroča klinične odpornosti na abakavir.
M2 and M3 metabolites were all shown to be pharmacologically active in an animal pharmacodynamic model, where M3 was most potent and M2 least active.
Za presnovke M1, M2 in M3 so na živalskem farmakodinamičnem modelu dokazali, da so farmakološko aktivni, pri čemer je bil M3 najbolj, M2 pa najmanj aktiven.
m2 intravenous 22 hr
intravensko 22 h
M296I
M296L
M296T
M296V
M2’ and M3’, the major metabolites in human faeces, were formed from M2 and lenvatinib, respectively, by aldehyde oxidase.
M2’ in M3’, poglavitna presnovka v človeškem blatu, sta nastala iz M2 oziroma lenvatiniba z aldehidno oksidazo.
M3 receptors mediate contraction of airway smooth muscle.
Receptorji M3 posredno vplivajo na krčenje gladkih mišic dihalnih poti.
M3 receptors mediate contraction of airway smooth muscle.
Receptorji M3 posredujejo krčenje gladkih mišic dihalnih poti.
M8 metabolite AUC ↑ 74%
AUC presnovka M8 ↑ 74
M8 metabolite AUC ↑ 86%
AUC nelfinavirja ↑ 39 % AUC presnovka M8 ↑ 86
M8 metabolite AUC ↑ 86%
AUC presnovka M8 ↑ 86
M98-940 was an open-label study of a liquid formulation of Kaletra in 100 antiretroviral naïve (44%) and experienced (56%) paediatric patients.
M98-940 je odprta študija tekočega pripravka zdravila Kaletra pri 100 protiretrovirusno naivnih (44%) in izkušenih (56%) pediatričnih bolnikih.
M98-940 was an open-label study of a liquid formulation of lopinavir/ritonavir in 100 antiretroviral naïve (44%) and experienced (56%) paediatric patients.
M98-940 je odprta študija tekočega pripravka lopinavirja/ritonavirja pri 100 protiretrovirusno nezdravljenih (44%) in izkušenih (56%) pediatričnih bolnikih.
m: months
m: meseci
MA (EU)  number
Številka (EU) dovoljenja za promet
MA (EU) number
EU številka
MA (EU) Number
EU/1/11/706/028
MA (EU) number
nastavkom
MA (EU) number
za promet
MA (EU) number (Invented)
EU/1/07/431/044
MA (EU) number (Invented)
Needle-Trap
MA 01605 USA
MA 01605 ZDA
MA 01701-9322 USA
MA 01701-9322 ZDA
MA 01757 UNITED STATES
MA 01757 ZDA
MA 02141 USA
Cambridge MA 02141 USA
MabCampath 10 mg/ml concentrate for solution for infusion
MabCampath 10 mg/ml koncentrat za raztopino za infundiranje
MabCampath 30 mg/ml concentrate for solution for infusion
MabCampath 30 mg/ml koncentrat za raztopino za infundiranje
MabCampath contains no antimicrobial preservatives, therefore, it is recommended that MabCampath should be prepared for intravenous infusion using aseptic techniques and that the diluted solution for infusion should be administered within 8 hours after preparation and protected from light.
Zdravilo MabCampath ne vsebuje protimikrobnih konzervansov, zato ga morate za intravensko infuzijo pripraviti aseptično, razredčeno raztopino za infundiranje pa uporabiti v 8 urah po pripravi in jo zaščititi pred svetlobo.
MabCampath is a concentrate for solution for infusion that comes in a glass ampoule.
Zdravilo MabCampath je na voljo v stekleni ampuli v obliki koncentrata za raztopino za infundiranje.
MabCampath is a concentrate for solution for infusion that comes in a glass vial.
Zdravilo MabCampath je na voljo v stekleni viali v obliki koncentrata za raztopino za infundiranje.
MabCampath is administered into one of your veins via a drip (see also ‘information intended for medical or healthcare professionals’).
Infundiranje zdravila MabCampath poteka preko infuzijske cevke v eno od vaših ven (glejte tudi informacije namenjene zdravstvenemu osebju).
MabCampath is indicated for the treatment of patients with B-cell chronic lymphocytic leukaemia (B- CLL) for whom fludarabine combination chemotherapy is not appropriate.
Zdravilo MabCampath je indicirano za zdravljenje bolnikov z B-celično kronično limfocitno levkemijo (B-KLL), za katere kemoterapija s fludarabinom ni primerna.
MabCampath is not recommended in children below 17 years of age or in patients who have kidney or liver disorders.
Uporaba zdravila MabCampath ni priporočljiva pri otrocih mlajših od 17 let in bolnikih z boleznimi ledvic ali jeter.
MabCampath is not recommended in children below 17 years of age or in patients who have kidney or liver disorders.
Uporaba zdravila MabCampath ni priporočljiva pri otrocih mlajših od 17 let in pri bolnikih z boleznimi ledvic ali jeter.
MabCampath must not be administered to patients who are pregnant, therefore if you:
Nosečnice ne smejo dobivati zdravila MabCampath, zato morate
MabCampath should be administered under the supervision of a physician experienced in the use of cancer therapy.
Zdravljenje z zdravilom MabCampath mora potekati pod nadzorom zdravnika z izkušnjami pri onkološkem zdravljenju.
MabCampath should be permanently discontinued if autoimmune anaemia or autoimmune thrombocytopenia appears.
Uporabo zdravila MabCampath je treba trajno prekiniti, če pride do pojava avtoimunske anemije ali avtoimunske trombocitopenije.
MabCampath should be used within 8 hours after dilution.
Uporabiti ga je treba v 8 urah po razredčenju.
MabCampath was originally authorised under ‘exceptional circumstances’, because, for scientific reasons, it had not been possible to obtain complete information on the medicine.
Zdravilo MabCampath je bilo prvotno odobreno „v izjemnih okoliščinah“, saj zaradi znanstvenih razlogov ni bilo mogoče pridobiti vseh informacij o zdravilu.
MabThera (N=167)
MabThera (n = 167)
MabThera 100 mg concentrate for solution for infusion
MabThera 100 mg koncentrat za raztopino za infundiranje
MabThera 100 mg concentrate for solution for infusion Rituximab
MabThera 100 mg koncentrat za raztopino za infundiranje rituksimab
MabThera 1400 mg is used to treat Non-Hodgkin’s lymphoma in adults.
Zdravilo MabThera 1400 mg se uporablja za zdravljenje ne-Hodgkinovega limfoma pri odraslih.
MabThera 1400 mg solution for subcutaneous injection
MabThera 1400 mg raztopina za podkožno injiciranje
MabThera 1400 mg solution for subcutaneous injection rituximab subcutaneous
MabThera 1400 mg raztopina za podkožno injiciranje rituksimab subkutano
MabThera 1400 mg subcutaneous formulation should be administered as subcutaneous injection only, over approximately 5 minutes.
Podkožno obliko zdravila MabThera 1400 mg se sme dati le podkožno; zdravilo je treba injicirati približno 5 minut.
MabThera 1600 mg is used to treat chronic lymphocytic leukaemia -in adults.
Zdravilo MabThera 1600 mg se uporablja za zdravljenje kronične limfocitne levkemije pri odraslih.
MabThera 1600 mg solution for subcutaneous injection
MabThera 1600 mg raztopina za podkožno injiciranje
MabThera 1600 mg solution for subcutaneous injection rituximab subcutaneous
MabThera 1600 mg raztopina za podkožno injiciranje rituksimab subkutano
MabThera 1600 mg subcutaneous formulation should be administered as subcutaneous injection only, over approximately 7 minutes.
Podkožno obliko zdravila MabThera 1600 mg se sme dati le podkožno; zdravilo je treba injicirati približno 7 minut.
MabThera 500 mg concentrate for solution for infusion
MabThera 500 mg koncentrat za raztopino za infundiranje
MabThera 500 mg concentrate for solution for infusion Rituximab
MabThera 500 mg koncentrat za raztopino za infundiranje rituksimab
MabThera Alert Card for patients with non-oncology diseases
Opozorilna izkaznica za bolnike, ki prejemajo zdravilo MabThera za neonkološke bolezni
MabThera contains the active substance “rituximab”.
Zdravilo MabThera vsebuje zdravilno učinkovino rituksimab.
MabThera in combination with chemotherapy destroys these cells which are gradually removed from the body by biological processes-.
Zdravilo MabThera v kombinaciji s kemoterapijo uniči te celice, ki se postopno odstranijo iz telesa z biološkimi procesi.
MabThera in combination with methotrexate significantly increased the proportion of patients achieving at least a 20 % improvement in ACR score compared with patients treated with methotrexate alone (Table 10).
Zdravilo MabThera v kombinaciji z metotreksatom je značilno povečalo delež bolnikov, ki so dosegli najmanj 20-% izboljšanje glede na ACR oceno v primerjavi z bolniki, ki so se zdravili samo z metotreksatom (preglednica 10).
MabThera in combination with methotrexate significantly increased the proportion of patients achieving at least a 20% improvement in ACR score compared with patients treated with methotrexate alone (Table 10).
Zdravilo MabThera v kombinaciji z metotreksatom je značilno povečalo delež bolnikov, ki so dosegli najmanj 20-% izboljšanje glede na ACR oceno v primerjavi z bolniki, ki so se zdravili samo z metotreksatom (preglednica 10).
MabThera intravenous
MabThera intravensko
MabThera intravenous (n= 88): 1st cycle of MabThera intravenous 375 mg/m2 in combination with chemotherapy followed by up to 5 cycles of MabThera intravenous 500 mg/m2 in combination with chemotherapy.
Intravenska oblika zdravila MabThera (n = 88): prvi cikel z intravensko obliko zdravila MabThera v odmerku 375 mg/m2 telesne površine v kombinaciji s kemoterapijo, ki mu je sledilo 5 ciklov intravenske oblike zdravila MabThera v odmerku 500 mg/m2 telesne površine v kombinaciji s kemoterapijo.
MabThera intravenous formulation (n= 205): 8 cycles of MabThera intravenous formulation in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks.
Intravenska oblika zdravila MabThera (n = 205): 8 ciklov z intravensko obliko zdravila MabThera v kombinaciji z do 8 cikli kemoterapije CHOP ali CVP, uporabljene enkrat na 3 tedne.
MabThera intravenous formulation was used at the standard dose of 375 mg/m2 body surface area.
Intravenska oblika zdravila MabThera je bila uporabljena v standardnem odmerku 375 mg/m2 telesne površine.
MabThera is a medicine used to treat the following blood cancers and inflammatory conditions:
MabThera je zdravilo za zdravljenje naslednjih vrst krvnega raka in vnetnih stanj:
MabThera is associated with infusion related reactions (IRRs), which may be related to release of cytokines and/or other chemical mediators.
Zdravilo MabThera lahko povzroči reakcije, povezane z infuzijo, ki nastanejo zaradi sprostitve citokinov in/ali drugih kemičnih mediatorjev.
MabThera is associated with infusion/ related reactions, which may be related to release of cytokines and/or other chemical mediators.
Zdravilo MabThera lahko spremljajo reakcije, povezane z infuzijo, ki morda nastanejo zaradi sprostitve citokinov in/ali drugih kemičnih mediatorjev.
MabThera is associated with infusionrelated reactions, which may be related to release of cytokines and/or other chemical mediators.
Zdravilo MabThera lahko spremljajo reakcije, povezane z infuzijo, ki morda nastanejo zaradi sprostitve citokinov in/ali drugih kemičnih mediatorjev.
MabThera is available as a concentrate that is made up into the solution for infusion and as a ready- made solution for the injection under the skin.
Zdravilo MabThera je na voljo v obliki koncentrata za pripravo raztopine za infundiranje in v obliki pripravljene raztopine za injiciranje v podkožje.
MabThera is available as a medicine given as a drip (called MabThera 100 mg or MabThera 500 mg, concentrate for solution for infusion) and as a medicine for injection under your skin: called MabThera 1400 mg or MabThera 1600 mg, solution for subcutaneous injection).
Zdravilo MabThera je na voljo v obliki za infundiranje v veno (z imenoma MabThera 100 mg in MabThera 500 mg koncentrat za raztopino za infundiranje) in v obliki za injiciranje pod kožo (z imenom MabThera 1400 mg ali MabThera 1600 mg raztopina za podkožno injiciranje).
MabThera is indicated for the treatment of patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.
Zdravilo MabThera je indicirano za zdravljenje bolnikov s CD20-pozitivnim difuznim velikoceličnim B ne-Hodgkinovim limfomom v kombinaciji s kemoterapijo CHOP (ciklofosfamid, doksirubicin, vinkristin, prednizolon).
MabThera is indicated in adults for Non-Hodgkin’s lymphoma (NHL):
Zdravilo MabThera je indicirano pri odraslih za zdravljenje ne-Hodgkinovega limfoma (NHL):
MabThera is indicated in adults for the following indications: Non-Hodgkin’s lymphoma (NHL)
Zdravilo MabThera je pri odraslih indicirano za naslednje indikacije: Ne-Hodgkinov limfom (NHL)
MabThera is used for inducing remission in granulomatosis with polyangiitis (formerly called Wegener’s granulomatosis) or microscopic polyangiitis, taken in combination with corticosteroids.
Zdravilo MabThera se uporablja za spodbujanje umirjanja bolezni pri granulomatozi s poliangiitisom (prej imenovani Wegenerjeva granulomatoza) ali pri mikroskopskem poliangiitisu; daje se v kombinaciji s kortikosteroidi.
MabThera is used to treat rheumatoid arthritis in people who have already tried some other medicines which have either stopped working, have not worked well enough or have caused side effects.
Zdravilo MabThera se uporablja za zdravljenje revmatoidnega artritisa pri bolnikih, ki so se že zdravili z drugimi zdravili, vendar so prenehala delovati, niso bila dovolj učinkovita ali pa so povzročala neželene učinke.
MabThera maintenance treatment consisted of a single infusion of MabThera at 375 mg/m2 body surface area given every 2 months until disease progression or for a maximum period of two years.
V okviru vzdrževalnega zdravljenja so bolniki prejeli eno infuzijo zdravila MabThera v odmerku 375 mg/m2 telesne površine vsaka 2 meseca do napredovanja bolezni ali največ dve leti.
MabThera maintenance treatment provided consistent benefit in all predefined subgroups tested: gender (male, female), age (< 60 years, >= 60 years), FLIPI score (<=1, 2 or >= 3), induction therapy (R-CHOP, R-CVP or R-FCM) and regardless of the quality of response to induction treatment (CR, CRu or PR).
Vzdrževalno zdravljenje z zdravilom MabThera je pokazalo konsistentno korist pri vseh preiskovanih, vnaprej opredeljenih podskupinah glede na spol (moški, ženski), starost (< 60 let, ≥ 60 let), oceno po indeksu FLIPI (Follicular Lymphoma International Prognostic Index) (≤ 1, 2 ali ≥ 3), indukcijsko zdravljenje (R-CHOP, R-CVP ali R-FCM) in ne glede na odgovor na indukcijsko zdravljenje (CR/CRu ali PR).
MabThera maintenance treatment provided consistent benefit in all predefined subgroups tested: gender (male, female), age (< 60 years, >= 60 years), FLIPI score (<=1, 2 or >= 3), induction therapy (R-CHOP, R-CVP or R-FCM) and regardless of the quality of response to induction treatment (CR/CRu or PR).
Vzdrževalno zdravljenje z zdravilom MabThera je pokazalo konsistentno korist pri vseh preiskovanih, vnaprej opredeljenih podskupinah glede na spol (moški, ženski), starost (< 60 let, ≥ 60 let), oceno po indeksu FLIPI (Follicular Lymphoma International Prognostic Index) (≤ 1, 2 ali ≥ 3), indukcijsko zdravljenje (R-CHOP, R-CVP ali R-FCM) in ne glede na odgovor na indukcijsko zdravljenje (CR/CRu ali PR).